TearScience Launches Breakthrough Technology in Canada to Address the Root Cause of Evaporative Dry Eye

TearScience Introduces LipiView® and LipiFlow® Devices at Canadian Ophthalmic Society Exhibition

Canadian Ophthalmic Society (COS) Exhibition

MORRISVILE, N.C.--()--TearScience, Inc., a privately-held medical device company, today announced the product launch of its LipiView® Ocular Surface Interferometer and LipiFlow® Thermal Pulsation medical devices in Canada. TearScience’s devices were designed to help eye care physicians address a root cause of evaporative dry eye, Meibomian Gland Dysfunction (MGD), which results in a lipid deficiency of the eye’s natural tear film. LipiView® helps physicians visualize the eye’s natural tear film. LipiFlow® is designed to alleviate meibomian gland obstructions by applying a precise combination of directed energy to eyelids during a 12 minute in-office treatment.

TearScience will demonstrate its devices at the Canadian Ophthalmic Society (COS) exhibition on June 9-12, 2011 at the Westin Bayshore Hotel in Vancouver at booth #28.

“TearScience is introducing a revolutionary technology as a new alternative to traditional treatments for Meibomian Gland Dysfunction,” said Jeff O’Hara, vice president of sales for TearScience. “Our goal is to help physicians make a meaningful difference for those who suffer from chronic evaporative dry eye.”

Herzig Eye Institute of Toronto is one of the first eye care practices in North America to implement TearScience’s system and has begun treating patients over the last several months.

Of the more than 100 million dry eye sufferers worldwide, approximately 65 percent have evaporative dry eye. Common symptoms of the disease include eye irritation, dryness, redness, tiredness, and visual disturbances.

In a randomized, controlled, multi-center clinical trial involving 139 patients, which compared the LipiFlow® System to iHeat™ warm compresses therapy for the treatment of Meibomian Gland Dysfunction, the total meibomian gland secretion score improved in 90 percent of patients at 4 weeks. Additionally, dry eye symptoms were improved from before the LipiFlow® treatment in 84-88 percent of patients at four weeks based on two different recognized symptom questionnaires, Standard Patient Evaluation of Eye Dryness (SPEED) and Ocular Surface Disease Index (OSDI).

TearScience will sell its LipiView® and LipiFlow® devices as a system to eye care practices. LipiView® recently won the Medical Design of Excellence Award from UBM Canon.

About TearScience, Inc.

Headquartered in Morrisville, North Carolina, TearScience has pioneered devices that provide significant clinical improvement in the treatment of evaporative dry eye. Of the more than 100 million dry eye sufferers worldwide, approximately 65 percent have evaporative dry eye, which is caused by Meibomian Gland Dysfunction and a lipid deficiency of the eye’s natural tear film. TearScience’s integrated, in-office system is the first to enable eye care professionals to address a root cause of evaporative dry eye. For additional information, visit www.tearscience.com.

Contacts

TearScience
Mary Hecht-Kissell, 919-459-4803
mhkissell@tearscience.com

Release Summary

TearScience is launching its LipiView® and LipiFlow® medical devices, which are designed to help eye care physicians help patients address a root cause of evaporate dry eye, in Canada.

Sharing

Contacts

TearScience
Mary Hecht-Kissell, 919-459-4803
mhkissell@tearscience.com